ID   PARD3_RAT               Reviewed;        1337 AA.
AC   Q9Z340;
DT   16-MAY-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   24-JUL-2024, entry version 189.
DE   RecName: Full=Partitioning defective 3 homolog;
DE            Short=PAR-3;
DE            Short=PARD-3;
DE   AltName: Full=Atypical PKC isotype-specific-interacting protein;
DE            Short=ASIP;
DE   AltName: Full=Atypical PKC-specific-binding protein;
DE            Short=ASBP;
GN   Name=Pard3; Synonyms=Par3;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH PRKCI AND
RP   PRKCZ.
RC   TISSUE=Fibroblast;
RX   PubMed=9763423; DOI=10.1083/jcb.143.1.95;
RA   Izumi Y., Hirose T., Tamai Y., Hirai S., Nagashima Y., Fujimoto T.,
RA   Tabuse Y., Kemphues K.J., Ohno S.;
RT   "An atypical PKC directly associates and colocalizes at the epithelial
RT   tight junction with ASIP, a mammalian homologue of Caenorhabditis elegans
RT   polarity protein PAR-3.";
RL   J. Cell Biol. 143:95-106(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION AT SER-827.
RX   PubMed=12045219; DOI=10.1242/jcs.115.12.2485;
RA   Hirose T., Izumi Y., Nagashima Y., Tamai-Nagai Y., Kurihara H., Sakai T.,
RA   Suzuki Y., Yamanaka T., Suzuki A., Mizuno K., Ohno S.;
RT   "Involvement of ASIP/PAR-3 in the promotion of epithelial tight junction
RT   formation.";
RL   J. Cell Sci. 115:2485-2495(2002).
RN   [3]
RP   FUNCTION IN REGULATION OF PERIPHERAL MYELINATION, ACETYLATION, AND
RP   DEACETYLATION BY SIRT2.
RX   PubMed=21949390; DOI=10.1073/pnas.1104969108;
RA   Beirowski B., Gustin J., Armour S.M., Yamamoto H., Viader A., North B.J.,
RA   Michan S., Baloh R.H., Golden J.P., Schmidt R.E., Sinclair D.A., Auwerx J.,
RA   Milbrandt J.;
RT   "Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through
RT   polarity protein Par-3/atypical protein kinase C (aPKC) signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:E952-961(2011).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-174 AND SER-852, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [5]
RP   STRUCTURE BY NMR OF 2-83, SUBCELLULAR LOCATION, AND DOMAIN.
RX   PubMed=17476308; DOI=10.1038/sj.emboj.7601702;
RA   Feng W., Wu H., Chan L.N., Zhang M.;
RT   "The Par-3 NTD adopts a PB1-like structure required for Par-3
RT   oligomerization and membrane localization.";
RL   EMBO J. 26:2786-2796(2007).
RN   [6]
RP   STRUCTURE BY NMR OF 454-550, SUBCELLULAR LOCATION, FUNCTION,
RP   PHOSPHOINOSITOL LIPID BINDING, DOMAIN, MUTAGENESIS OF LYS-458; LYS-491;
RP   ARG-504; LYS-506; ARG-532; LYS-535 AND ARG-546, AND INTERACTION WITH PTEN.
RX   PubMed=18082612; DOI=10.1016/j.molcel.2007.10.028;
RA   Wu H., Feng W., Chen J., Chan L.N., Huang S., Zhang M.;
RT   "PDZ domains of Par-3 as potential phosphoinositide signaling
RT   integrators.";
RL   Mol. Cell 28:886-898(2007).
RN   [7]
RP   STRUCTURE BY NMR OF 582-685 IN COMPLEX WITH PTEN, SUBUNIT, SUBCELLULAR
RP   LOCATION, AND FUNCTION.
RX   PubMed=18550519; DOI=10.1074/jbc.m802482200;
RA   Feng W., Wu H., Chan L.N., Zhang M.;
RT   "Par-3-mediated junctional localization of the lipid phosphatase PTEN is
RT   required for cell polarity establishment.";
RL   J. Biol. Chem. 283:23440-23449(2008).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 813-840 IN COMPLEX WITH MOUSE
RP   PRKCI, PHOSPHORYLATION AT SER-827, AND MUTAGENESIS OF SER-827 AND SER-829.
RX   PubMed=22579248; DOI=10.1016/j.str.2012.02.022;
RA   Wang C., Shang Y., Yu J., Zhang M.;
RT   "Substrate recognition mechanism of atypical protein kinase Cs revealed by
RT   the structure of PKCiota in complex with a substrate peptide from Par-3.";
RL   Structure 20:791-801(2012).
CC   -!- FUNCTION: Adapter protein involved in asymmetrical cell division and
CC       cell polarization processes (PubMed:18550519). Seems to play a central
CC       role in the formation of epithelial tight junctions (By similarity).
CC       Association with PARD6B may prevent the interaction of PARD3 with
CC       F11R/JAM1, thereby preventing tight junction assembly (By similarity).
CC       The PARD6-PARD3 complex links GTP-bound Rho small GTPases to atypical
CC       protein kinase C proteins (By similarity). Required for establishment
CC       of neuronal polarity and normal axon formation in cultured hippocampal
CC       neurons (By similarity). Involved in Schwann cell peripheral
CC       myelination (PubMed:21949390). Targets the phosphatase PTEN to cell
CC       junctions (PubMed:18082612). {ECO:0000250|UniProtKB:Q8TEW0,
CC       ECO:0000250|UniProtKB:Q99NH2, ECO:0000269|PubMed:18082612,
CC       ECO:0000269|PubMed:18550519, ECO:0000269|PubMed:21949390}.
CC   -!- SUBUNIT: Component of a complex whose core is composed of ARHGAP17,
CC       AMOT, PALS1, PATJ and PARD3/PAR3. Interacts (via PDZ 1 domain) with
CC       PARD6A, PARD6B and F11R/JAM1. Interacts with AURKA, AURKB and SIRT2 (By
CC       similarity). Interacts with PRKCI. Interacts with PRKCZ (Probable).
CC       Part of a complex with PARD6A or PARD6B, PRKCI or PRKCZ and CDC42 or
CC       RAC1. Interacts with LIMK2 and CDH5. Component of the Par polarity
CC       complex, composed of at least phosphorylated PRKCZ, PARD3 and TIAM1.
CC       Directly interacts with TIAM1 and TIAM2. Interacts with ECT2 and FBF1
CC       (By similarity). Interacts (via PDZ 3 domain) with PTEN (via C-
CC       terminus). Interacts (via coiled-coil domain) with FRMD4A (By
CC       similarity). Found in a complex with PARD3, CYTH1 and FRMD4A (By
CC       similarity). Interacts with SAPCD2 (By similarity). Interacts with
CC       PRKCA (By similarity). {ECO:0000250|UniProtKB:Q8TEW0,
CC       ECO:0000250|UniProtKB:Q99NH2, ECO:0000269|PubMed:18082612,
CC       ECO:0000269|PubMed:18550519, ECO:0000269|PubMed:22579248,
CC       ECO:0000269|PubMed:9763423, ECO:0000305}.
CC   -!- SUBUNIT: [Isoform 2]: Interacts with PRKCZ.
CC       {ECO:0000250|UniProtKB:Q99NH2}.
CC   -!- INTERACTION:
CC       Q9Z340; Q9Z340: Pard3; NbExp=6; IntAct=EBI-349441, EBI-349441;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Endomembrane system.
CC       Cell junction. Cell junction, tight junction
CC       {ECO:0000250|UniProtKB:Q99NH2}. Cell junction, adherens junction
CC       {ECO:0000250|UniProtKB:Q99NH2}. Cytoplasm, cell cortex {ECO:0000250}.
CC       Cytoplasm, cytoskeleton {ECO:0000250}. Cell membrane {ECO:0000250}.
CC       Note=Localized along the cell-cell contact region. Colocalizes with
CC       PARD6A and PRKCI at epithelial tight junctions. Colocalizes with the
CC       cortical actin that overlays the meiotic spindle during metaphase I and
CC       metaphase II. Presence of KRIT1, CDH5 and RAP1B is required for its
CC       localization to the cell junction. Colocalized with SIRT2 in internode
CC       region of myelin sheath (By similarity). {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=180 kDa;
CC         IsoId=Q9Z340-1; Sequence=Displayed;
CC       Name=2; Synonyms=150 kDa;
CC         IsoId=Q9Z340-2; Sequence=VSP_007475;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is predominantly expressed in lung,
CC       glandular stomach, prostate, ovary and uterus. Isoform 1 is also
CC       expressed in brain, with a high expression in the cortex, hippocampus
CC       and in the striatum. Isoform 2 is predominantly expressed in intestinal
CC       epithelial cells, kidney and prostate.
CC   -!- DOMAIN: Contains a conserved N-terminal oligomerization domain (NTD)
CC       that is involved in oligomerization and is essential for proper
CC       subapical membrane localization.
CC   -!- DOMAIN: The second PDZ domain mediates interaction with membranes
CC       containing phosphoinositol lipids.
CC   -!- PTM: Acetylated. Deacetylated by SIRT2, thereby inhibiting Schwann cell
CC       peripheral myelination. {ECO:0000269|PubMed:21949390}.
CC   -!- PTM: Phosphorylation at Ser-827 by PRKCZ and PRKCI occurs at the most
CC       apical tip of epithelial cell-cell contacts during the initial phase of
CC       tight junction formation and may promote dissociation of the complex
CC       with PARD6. EGF-induced Tyr-1127 phosphorylation mediates dissociation
CC       from LIMK2 (By similarity). Phosphorylation by AURKA at Ser-962 is
CC       required for the normal establishment of neuronal polarity (By
CC       similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the PAR3 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB005549; BAA34216.1; -; mRNA.
DR   PIR; T13948; T13948.
DR   RefSeq; NP_112514.1; NM_031235.1. [Q9Z340-1]
DR   PDB; 2K1Z; NMR; -; A=582-685.
DR   PDB; 2K20; NMR; -; A=582-685.
DR   PDB; 2NS5; NMR; -; A=2-83.
DR   PDB; 2OGP; NMR; -; A=454-550.
DR   PDB; 3ZEE; EM; 6.10 A; A=2-82.
DR   PDB; 4DC2; X-ray; 2.40 A; Z=813-840.
DR   PDB; 4I6P; X-ray; 2.90 A; A/B=2-83.
DR   PDB; 6JUE; X-ray; 1.55 A; L=582-685.
DR   PDBsum; 2K1Z; -.
DR   PDBsum; 2K20; -.
DR   PDBsum; 2NS5; -.
DR   PDBsum; 2OGP; -.
DR   PDBsum; 3ZEE; -.
DR   PDBsum; 4DC2; -.
DR   PDBsum; 4I6P; -.
DR   PDBsum; 6JUE; -.
DR   AlphaFoldDB; Q9Z340; -.
DR   SMR; Q9Z340; -.
DR   BioGRID; 249693; 4.
DR   CORUM; Q9Z340; -.
DR   DIP; DIP-33271N; -.
DR   IntAct; Q9Z340; 2.
DR   MINT; Q9Z340; -.
DR   STRING; 10116.ENSRNOP00000048964; -.
DR   iPTMnet; Q9Z340; -.
DR   PhosphoSitePlus; Q9Z340; -.
DR   PaxDb; 10116-ENSRNOP00000048964; -.
DR   Ensembl; ENSRNOT00000042623.5; ENSRNOP00000048964.4; ENSRNOG00000032437.6. [Q9Z340-1]
DR   Ensembl; ENSRNOT00055008550; ENSRNOP00055006489; ENSRNOG00055005278. [Q9Z340-1]
DR   Ensembl; ENSRNOT00060008814; ENSRNOP00060006651; ENSRNOG00060005209. [Q9Z340-1]
DR   Ensembl; ENSRNOT00065032696; ENSRNOP00065026121; ENSRNOG00065019347. [Q9Z340-1]
DR   GeneID; 81918; -.
DR   KEGG; rno:81918; -.
DR   UCSC; RGD:620374; rat. [Q9Z340-1]
DR   AGR; RGD:620374; -.
DR   CTD; 56288; -.
DR   RGD; 620374; Pard3.
DR   eggNOG; KOG3528; Eukaryota.
DR   GeneTree; ENSGT00950000183214; -.
DR   HOGENOM; CLU_006629_0_0_1; -.
DR   InParanoid; Q9Z340; -.
DR   OMA; ADDKDRX; -.
DR   OrthoDB; 5405986at2759; -.
DR   PhylomeDB; Q9Z340; -.
DR   Reactome; R-RNO-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition).
DR   Reactome; R-RNO-420029; Tight junction interactions.
DR   EvolutionaryTrace; Q9Z340; -.
DR   PRO; PR:Q9Z340; -.
DR   Proteomes; UP000002494; Chromosome 19.
DR   Bgee; ENSRNOG00000032437; Expressed in esophagus and 19 other cell types or tissues.
DR   ExpressionAtlas; Q9Z340; baseline and differential.
DR   GO; GO:0005912; C:adherens junction; ISO:RGD.
DR   GO; GO:0043296; C:apical junction complex; ISO:RGD.
DR   GO; GO:0045177; C:apical part of cell; ISO:RGD.
DR   GO; GO:0016324; C:apical plasma membrane; IBA:GO_Central.
DR   GO; GO:0044295; C:axonal growth cone; IDA:RGD.
DR   GO; GO:0005923; C:bicellular tight junction; ISS:UniProtKB.
DR   GO; GO:0005938; C:cell cortex; IBA:GO_Central.
DR   GO; GO:0030054; C:cell junction; ISO:RGD.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0012505; C:endomembrane system; IEA:UniProtKB-SubCell.
DR   GO; GO:0033269; C:internode region of axon; ISS:UniProtKB.
DR   GO; GO:0043219; C:lateral loop; ISO:RGD.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0120157; C:PAR polarity complex; ISO:RGD.
DR   GO; GO:0032991; C:protein-containing complex; IDA:RGD.
DR   GO; GO:0043220; C:Schmidt-Lanterman incisure; ISO:RGD.
DR   GO; GO:0005819; C:spindle; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0035091; F:phosphatidylinositol binding; IBA:GO_Central.
DR   GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; IDA:UniProtKB.
DR   GO; GO:0032266; F:phosphatidylinositol-3-phosphate binding; IDA:UniProtKB.
DR   GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; IDA:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0003383; P:apical constriction; ISO:RGD.
DR   GO; GO:0070830; P:bicellular tight junction assembly; IMP:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; IBA:GO_Central.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0051642; P:centrosome localization; ISO:RGD.
DR   GO; GO:0030010; P:establishment of cell polarity; IBA:GO_Central.
DR   GO; GO:0051660; P:establishment of centrosome localization; IBA:GO_Central.
DR   GO; GO:0090162; P:establishment of epithelial cell polarity; IMP:UniProtKB.
DR   GO; GO:0045197; P:establishment or maintenance of epithelial cell apical/basal polarity; ISO:RGD.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; ISO:RGD.
DR   GO; GO:0022011; P:myelination in peripheral nervous system; ISS:UniProtKB.
DR   GO; GO:0010801; P:negative regulation of peptidyl-threonine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0031643; P:positive regulation of myelination; ISS:UniProtKB.
DR   GO; GO:0002092; P:positive regulation of receptor internalization; ISO:RGD.
DR   GO; GO:0008104; P:protein localization; IBA:GO_Central.
DR   GO; GO:0006612; P:protein targeting to membrane; IDA:UniProtKB.
DR   GO; GO:0032970; P:regulation of actin filament-based process; ISO:RGD.
DR   GO; GO:0060341; P:regulation of cellular localization; IMP:RGD.
DR   GO; GO:0044319; P:wound healing, spreading of cells; ISO:RGD.
DR   CDD; cd00992; PDZ_signaling; 3.
DR   Gene3D; 2.30.42.10; -; 3.
DR   InterPro; IPR052213; PAR3.
DR   InterPro; IPR021922; Par3/HAL_N.
DR   InterPro; IPR001478; PDZ.
DR   InterPro; IPR036034; PDZ_sf.
DR   PANTHER; PTHR16484:SF10; PARTITIONING DEFECTIVE 3 HOMOLOG; 1.
DR   PANTHER; PTHR16484; PARTITIONING DEFECTIVE 3 RELATED; 1.
DR   Pfam; PF12053; Par3_HAL_N_term; 1.
DR   Pfam; PF00595; PDZ; 3.
DR   SMART; SM00228; PDZ; 3.
DR   SUPFAM; SSF50156; PDZ domain-like; 3.
DR   PROSITE; PS50106; PDZ; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell cycle; Cell division;
KW   Cell junction; Cell membrane; Coiled coil; Cytoplasm; Cytoskeleton;
KW   Differentiation; Lipid-binding; Membrane; Phosphoprotein;
KW   Reference proteome; Repeat; Tight junction.
FT   CHAIN           1..1337
FT                   /note="Partitioning defective 3 homolog"
FT                   /id="PRO_0000185071"
FT   DOMAIN          271..359
FT                   /note="PDZ 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00143"
FT   DOMAIN          461..546
FT                   /note="PDZ 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00143"
FT   DOMAIN          590..677
FT                   /note="PDZ 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00143"
FT   REGION          81..109
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          143..263
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          397..441
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          712..936
FT                   /note="Interaction with PRKCI and PRKCZ"
FT                   /evidence="ECO:0000269|PubMed:9763423"
FT   REGION          866..888
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          932..1015
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          935..1337
FT                   /note="Interaction with FRMD4A"
FT                   /evidence="ECO:0000250|UniProtKB:Q99NH2"
FT   REGION          1028..1055
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1110..1271
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1284..1337
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          1050..1082
FT                   /evidence="ECO:0000255"
FT   COILED          1149..1172
FT                   /evidence="ECO:0000255"
FT   COILED          1199..1222
FT                   /evidence="ECO:0000255"
FT   COILED          1278..1299
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        88..109
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        146..187
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        188..202
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        203..224
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        959..976
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        978..1015
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1147..1176
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1177..1201
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1213..1244
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1284..1299
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         25
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TEW0"
FT   MOD_RES         91
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TEW0"
FT   MOD_RES         156
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99NH2"
FT   MOD_RES         174
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         383
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TEW0"
FT   MOD_RES         489
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TEW0"
FT   MOD_RES         692
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TEW0"
FT   MOD_RES         695
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TEW0"
FT   MOD_RES         715
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TEW0"
FT   MOD_RES         728
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TEW0"
FT   MOD_RES         809
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TEW0"
FT   MOD_RES         827
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12045219,
FT                   ECO:0000269|PubMed:22579248"
FT   MOD_RES         834
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99NH2"
FT   MOD_RES         837
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TEW0"
FT   MOD_RES         851
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99NH2"
FT   MOD_RES         852
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         873
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TEW0"
FT   MOD_RES         885
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99NH2"
FT   MOD_RES         962
FT                   /note="Phosphoserine; by AURKA"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TEW0"
FT   MOD_RES         971
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TEW0"
FT   MOD_RES         973
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TEW0"
FT   MOD_RES         1046
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TEW0"
FT   MOD_RES         1331
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99NH2"
FT   VAR_SEQ         1034..1337
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:12045219"
FT                   /id="VSP_007475"
FT   MUTAGEN         458
FT                   /note="K->E: Reduces binding to membranes containing
FT                   phosphoinositol lipids by half. Abolishes binding to
FT                   membranes containing phosphoinositol lipids; when
FT                   associated with E-546."
FT                   /evidence="ECO:0000269|PubMed:18082612"
FT   MUTAGEN         491
FT                   /note="K->A: Slightly reduced binding to membranes
FT                   containing phosphoinositol lipids."
FT                   /evidence="ECO:0000269|PubMed:18082612"
FT   MUTAGEN         491
FT                   /note="K->E: Strongly reduced binding to membranes
FT                   containing phosphoinositol lipids."
FT                   /evidence="ECO:0000269|PubMed:18082612"
FT   MUTAGEN         504
FT                   /note="R->A: Slightly reduced binding to membranes
FT                   containing phosphoinositol lipids; when associated with A-
FT                   506."
FT                   /evidence="ECO:0000269|PubMed:18082612"
FT   MUTAGEN         504
FT                   /note="R->E: Abolishes binding to membranes containing
FT                   phosphoinositol lipids; when associated with E-506."
FT                   /evidence="ECO:0000269|PubMed:18082612"
FT   MUTAGEN         506
FT                   /note="K->A: Slightly reduced binding to membranes
FT                   containing phosphoinositol lipids; when associated with A-
FT                   504."
FT                   /evidence="ECO:0000269|PubMed:18082612"
FT   MUTAGEN         506
FT                   /note="K->E: Abolishes binding to membranes containing
FT                   phosphoinositol lipids; when associated with E-504."
FT                   /evidence="ECO:0000269|PubMed:18082612"
FT   MUTAGEN         532
FT                   /note="R->A: Reduces binding to membranes containing
FT                   phosphoinositol lipids by half; when associated with A-
FT                   535."
FT                   /evidence="ECO:0000269|PubMed:18082612"
FT   MUTAGEN         532
FT                   /note="R->E: Almost abolished binding to membranes
FT                   containing phosphoinositol lipids; when associated with E-
FT                   535."
FT                   /evidence="ECO:0000269|PubMed:18082612"
FT   MUTAGEN         535
FT                   /note="K->A: Reduces binding to membranes containing
FT                   phosphoinositol lipids by half; when associated with A-
FT                   532."
FT                   /evidence="ECO:0000269|PubMed:18082612"
FT   MUTAGEN         535
FT                   /note="K->E: Almost abolished binding to membranes
FT                   containing phosphoinositol lipids; when associated with E-
FT                   532."
FT                   /evidence="ECO:0000269|PubMed:18082612"
FT   MUTAGEN         546
FT                   /note="R->E: Abolishes binding to membranes containing
FT                   phosphoinositol lipids; when associated with E-458."
FT                   /evidence="ECO:0000269|PubMed:18082612"
FT   MUTAGEN         827
FT                   /note="S->E: Abolishes binding to PKCI."
FT                   /evidence="ECO:0000269|PubMed:22579248"
FT   MUTAGEN         829
FT                   /note="S->A: No detectable impact on binding to PKCI."
FT                   /evidence="ECO:0000269|PubMed:22579248"
FT   MUTAGEN         829
FT                   /note="S->E: Abolishes binding to PKCI."
FT                   /evidence="ECO:0000269|PubMed:22579248"
FT   STRAND          2..7
FT                   /evidence="ECO:0007829|PDB:4I6P"
FT   STRAND          10..17
FT                   /evidence="ECO:0007829|PDB:4I6P"
FT   HELIX           23..38
FT                   /evidence="ECO:0007829|PDB:4I6P"
FT   STRAND          46..52
FT                   /evidence="ECO:0007829|PDB:4I6P"
FT   STRAND          54..56
FT                   /evidence="ECO:0007829|PDB:2NS5"
FT   HELIX           65..68
FT                   /evidence="ECO:0007829|PDB:4I6P"
FT   STRAND          74..81
FT                   /evidence="ECO:0007829|PDB:4I6P"
FT   STRAND          458..465
FT                   /evidence="ECO:0007829|PDB:2OGP"
FT   STRAND          472..477
FT                   /evidence="ECO:0007829|PDB:2OGP"
FT   STRAND          481..484
FT                   /evidence="ECO:0007829|PDB:2OGP"
FT   STRAND          488..493
FT                   /evidence="ECO:0007829|PDB:2OGP"
FT   STRAND          495..497
FT                   /evidence="ECO:0007829|PDB:2OGP"
FT   HELIX           498..502
FT                   /evidence="ECO:0007829|PDB:2OGP"
FT   STRAND          507..514
FT                   /evidence="ECO:0007829|PDB:2OGP"
FT   STRAND          520..522
FT                   /evidence="ECO:0007829|PDB:2OGP"
FT   HELIX           524..533
FT                   /evidence="ECO:0007829|PDB:2OGP"
FT   STRAND          539..546
FT                   /evidence="ECO:0007829|PDB:2OGP"
FT   STRAND          585..593
FT                   /evidence="ECO:0007829|PDB:6JUE"
FT   TURN            594..599
FT                   /evidence="ECO:0007829|PDB:2K1Z"
FT   STRAND          603..610
FT                   /evidence="ECO:0007829|PDB:6JUE"
FT   TURN            611..614
FT                   /evidence="ECO:0007829|PDB:6JUE"
FT   STRAND          615..624
FT                   /evidence="ECO:0007829|PDB:6JUE"
FT   HELIX           629..633
FT                   /evidence="ECO:0007829|PDB:6JUE"
FT   STRAND          641..645
FT                   /evidence="ECO:0007829|PDB:6JUE"
FT   STRAND          648..653
FT                   /evidence="ECO:0007829|PDB:2K1Z"
FT   HELIX           655..666
FT                   /evidence="ECO:0007829|PDB:6JUE"
FT   TURN            667..669
FT                   /evidence="ECO:0007829|PDB:2K20"
FT   STRAND          674..682
FT                   /evidence="ECO:0007829|PDB:6JUE"
SQ   SEQUENCE   1337 AA;  149448 MW;  EC980C5106B52F9C CRC64;
     MKVTVCFGRT RVVVPCGDGR MKVFSLIQQA VTRYRKAVAK DPNYWIQVHR LEHGDGGILD
     LDDILCDVAD DKDRLVAVFD EQDPHHGGDG TSASSTGTQS PEIFGSELGT NNVSAFRPYQ
     TTSEIEVTPS VLRANMPLHV RRSSDPALTG LSTSVSDNNF SSEEPSRKNP TRWSTTAGFL
     KQNTTGSPKT CDRKKDENYR SLPRDPSSWS NQFQRDNARS SLSASHPMVD RWLEKQEQDE
     EGTEEDSSRV EPVGHADTGL ENMPNFSLDD MVKLVQVPND GGPLGIHVVP FSARGGRTLG
     LLVKRLEKGG KAEQENLFHE NDCIVRINDG DLRNRRFEQA QHMFRQAMRA RVIWFHVVPA
     ANKEQYEQLS QREMNNYSPG RFSPDSHCVA NRSVANNAPQ ALPRAPRLSQ PPEQLDAHPR
     LPHSAHASTK PPTAPALAPP NVLSTSVGSV YNTKRVGKRL NIQLKKGTEG LGFSITSRDV
     TIGGSAPIYV KNILPRGAAI QDGRLKAGDR LIEVNGVDLA GKSQEEVVSL LRSTKMEGTV
     SLLVFRQEEA FHPREMNAEP SQMQSPKETK AEDEDIVLTP DGTREFLTFE VPLNDSGSAG
     LGVSVKGNRS KENHADLGIF VKSIINGGAA SKDGRLRVND QLIAVNGESL LGKANQEAME
     TLRRSMSTEG NKRGMIQLIV ARRISRCNEL RSPGSPAAPE LPIETELDDR ERRISHSLYS
     GIEGLDESPT RNAALSRIMG ESGKCQLSPT VNMPHDDTVM IEDDRLPVLP PHLSDQSSSS
     SHDDVGFIMT EAGTWAKATI SDSADCSLSP DVDPVLAFQR EGFGRQSMSE KRTKQFSNAS
     QLDFVKTRKS KSMDLGIADE TKLNTVDDQR AGSPNRDVGP SLGLKKSSSL ESLQTAVAEV
     TLNGNIPFHR PRPRIIRGRG CNESFRAAID KSYDKPMVDD DDEGMETLEE DTEESSRSGR
     ESVSTSSDQP SYSLERQMNG DPEKRDKAEK KKDKAGKDKK KDREKEKDKL KAKKGMLKGL
     GDMFRFGKHR KDDKMEKMGR IKIQDSFTSE EDRVRMKEEQ ERIQAKTREF RERQARERDY
     AEIQDFHRTF GCDDELLYGG MSSYDGCLAL NARPQSPREG HLMDTLYAQV KKPRSSKPGD
     SNRSTPSNHD RIQRLRQEFQ QAKQDEDVED RRRTYSFEQS WSSSRPASQS GRHSVSVEVQ
     VQRQRQEERE SFQQAQRQYS SLPRQSRKNA SSVSQDSWEQ NYAPGEGFQS AKENPRYSSY
     QGSRNGYLGG HGFNARVMLE TQELLRQEQR RKEQQLKKQP PADGVRGPFR QDVPPSPSQV
     ARLNRLQTPE KGRPFYS
//
